[Therapeutic targeting in breast cancer].
Penault-Llorca
Frédérique
F
Centre Jean-Perrin, rue Montalembert, Clermont-Ferrand cedex, France. fpenault@cip.fr
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000037:antagonists & inhibitors*; D001943:Breast Neoplasms / Q000737:chemistry / Q000145:classification / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002277:Carcinoma / Q000737:chemistry / Q000145:classification / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems / Q000379:methods*; D004967:Estrogens; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008408:Mastectomy; D009363:Neoplasm Proteins / Q000032:analysis / Q000037:antagonists & inhibitors*; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000145:classification / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D011374:Progesterone; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors; D011960:Receptors, Estrogen / Q000032:analysis / Q000037:antagonists & inhibitors; D011980:Receptors, Progesterone / Q000032:analysis / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D004967:Estrogens; D009363:Neoplasm Proteins; D011374:Progesterone; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human